Stahel, R.A.

A Multicentre Randomised Phase III Trial Comparing Pembrolizumab versus Single-Agent Chemotherapy for Advanced Pre-Treated Malignant Pleural Mesothelioma: The European Thoracic Oncology Platform (ETOP 9–15) PROMISE-Meso Trial

Popat, S., Curioni-Fontecedro, A., Dafni, U., Shah, R., O'Brien, M., Pope, A., Fisher, P., Spicer, J., Roy, A., Gilligan, D., et al. (2020) · Annals of Oncology

Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies

Cited by 271

ESMO guidance for reporting oncology real-world evidence (GROW)

Castelo-Branco, L., Pellat, A., Martins-Branco, D., Valachis, A., Derksen, J. W. G., Suijkerbuijk, K. P. M., Dafni, U., Dellaporta, T., Vogel, A., Prelaj, A., et al. (2023) · Annals of Oncology

Meta-analysis and systematic reviewsClinical practice guidelines implementation

Cited by 247

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): An international, multicentre, single-arm, phase 2 trial

Rosell, R., Dafni, U., Felip, E., Curioni-Fontecedro, A., Gautschi, O., Peters, S., Massutí, B., Palmero, R., Aix, S. P., Carcereny, E., et al. (2017) · The Lancet Respiratory Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 182

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial

Peters, S., Felip, E., Dafni, U., Belka, C., Guckenberger, M., Irigoyen, A., Nadal, E., Becker, A., Vees, H., Pless, M., et al. (2019) · Lung Cancer

Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 162

Hematopoietic Growth Factors Secreted by Seven Human Pleural Mesothelioma Cell Lines: Interleukin-6 Production as a Common Feature

Schmitter, D., Lauber, B., Fagg, B., & Stahel, R. A. (1992) · International Journal of Cancer

Occupational and environmental lung diseasesTGF-β signaling in diseases

Cited by 133